These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27329522)

  • 1. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
    PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-dimensional computational analysis of magnetic resonance images characterizes the biological aggressiveness in malignant brain tumours.
    Pérez-Beteta J; Martínez-González A; Pérez-García VM
    J R Soc Interface; 2018 Dec; 15(149):20180503. PubMed ID: 30958226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma.
    Pérez-Beteta J; Molina-García D; Martínez-González A; Henares-Molina A; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; Martino J; Velásquez C; Meléndez-Asensio B; de Lope ÁR; Moreno R; Barcia JA; Asenjo B; Benavides M; Herruzo I; Lara PC; Cabrera R; Albillo D; Navarro M; Pérez-Romasanta LA; Revert A; Arana E; Pérez-García VM
    Eur Radiol; 2019 Apr; 29(4):1968-1977. PubMed ID: 30324390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic Features on MR Imaging Classify Multifocal Glioblastomas in Different Prognostic Groups.
    Pérez-Beteta J; Molina-García D; Villena M; Rodríguez MJ; Velásquez C; Martino J; Meléndez-Asensio B; Rodríguez de Lope Á; Morcillo R; Sepúlveda JM; Hernández-Laín A; Ramos A; Barcia JA; Lara PC; Albillo D; Revert A; Arana E; Pérez-García VM
    AJNR Am J Neuroradiol; 2019 Apr; 40(4):634-640. PubMed ID: 30923085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
    Czarnek N; Clark K; Peters KB; Mazurowski MA
    J Neurooncol; 2017 Mar; 132(1):55-62. PubMed ID: 28074320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
    Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
    Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
    Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.
    Li C; Wang S; Serra A; Torheim T; Yan JL; Boonzaier NR; Huang Y; Matys T; McLean MA; Markowetz F; Price SJ
    Eur Radiol; 2019 Sep; 29(9):4718-4729. PubMed ID: 30707277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
    Pérez-Beteta J; Molina-García D; Ortiz-Alhambra JA; Fernández-Romero A; Luque B; Arregui E; Calvo M; Borrás JM; Meléndez B; Rodríguez de Lope Á; Moreno de la Presa R; Iglesias Bayo L; Barcia JA; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Revert A; Arana E; Pérez-García VM
    Radiology; 2018 Jul; 288(1):218-225. PubMed ID: 29924716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
    Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
    World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.
    Palmer JD; Bhamidipati D; Shukla G; Sharma D; Glass J; Kim L; Evans JJ; Judy K; Farrell C; Andrews DW; Wang ZW; Peiper SC; Werner-Wasik M; Shi W
    Am J Clin Oncol; 2019 May; 42(5):481-486. PubMed ID: 30973372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.